John Johnson is back trying his hand as a turnaround artist for a troubled biotech. Can he win this time?

John Johnson is once again trying his hand as a turnaround artist. The longtime biopharma exec has been named permanent CEO of the troubled Melinta Therapeutics $MLNT, which has been struggling to reorganize after building up a portfolio of antibiotics.